Logo (pure-white background + navy borde

Diverse Health Hub

  • Facebook
  • Twitter
  • Instagram

© 2020 Diverse Health Hub, LLC

Sickle Cell

Sickle cell disease is caused by a mutation with millions of people affected worldwide. Sickle cell is more common among people of certain ancestries, including those of African, Caribbean, Middle Eastern, Eastern Mediterranean, and Asian descent. Many disparities have been noted in the study of sickle cell disease. Through a series of educational programs, Diverse Health Hub will spotlight these important issues.

Sickle Cell Programs

Screen Shot 2019-12-15 at 10_edited.jpg

Are Sickle Cell Disease Patients More Susceptible to Renal Medullary Carcinoma?

Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center discusses whether patients with sickle cell disease or who carry the sickle cell trait may be at increased risk for renal medullary carcinoma (RMC).

Screen Shot 2019-12-15 at 10_edited.jpg

Will New Sickle Cell Disease Drugs Transform Quality of Care for Patients?

Dr. Andrew Campbell of Children's National shares his excitement around the increasing treatment arsenal in sickle cell disease and how this shift might allow for more personalized approaches in care. Campbell speaks to this new era of multi-drug approaches, gene therapy, and the hope that these tools provide global options to treat sickle cell disease.

Screen Shot 2019-12-15 at 10_edited.jpg

Multinational CASiRe - Will Sickle Cell Disease Clinicians & Trials Consider Diverse Populations?

Renowned expert, Dr. Andrew Campbell, Director of the CASiRe Consortium, provides an update on an international study of nearly 900 sickle cell disease patients from Ghana, Italy, United Kingdom and United States. The first of its kind, the study led by Dr. Campbell aims to understand the different phenotypes of SCD, comparing clinical profiles of SCD patients living around the world.

Screen Shot 2019-12-15 at 10_edited.jpg

Can Patients and Providers Eliminate Health Inequities in Treating Sickle Cell Disease?

Dr. Andrew Campbell shares how communities, patients, and providers can eliminate health inequities in Sickle Cell Disease (SCD). He asserts that awareness of SCD in the general population can secure resources and funding. Dr. Campbell emphasizes we investigate why adult and pediatric patients are receiving different levels of care.

Screen Shot 2019-12-15 at 10_edited.jpg

What Is Your Sickle Cell Disease Management Plan?

Dr. Ify Osunkwo of Levine Cancer Institute/Atrium Health discusses what patients can expect related to sickle cell disease management in the near future. Dr. Osunkwo emphasizes the importance of patients being proactive with their disease management plan in order to maximize quality of life and the effects on one's mortality while living with sickle cell disease (SCD).

Screen Shot 2019-12-15 at 10_edited.jpg

What Novel Tools Are Being Used to Treat Sickle Cell Disease?

Dr. Ify Osunkwo of Levine Cancer Institute/Atrium Health discusses new therapeutic tools used to treat Sickle Cell Disease (SCD) over the last few years and how they will impact patient quality of life. Can SCD be cured early before long-term organ damage occurs? Dr. Osunkwo spotlights the need for better drug therapy, and also shares in the buzz at ASH 2019 around gene therapy options for SCD.

Screen Shot 2019-12-15 at 10_edited.jpg

What Can Communities Do To Eliminate Disparities in Sickle Cell Disease?

Dr. Ify Osunkwo shares how we can combat disparities in sickle cell disease. Communities need to understand that Sickle Cell Disease (SCD) is genetic. Stop shaming and blaming patients. They need support and understanding. Not just providers need education, but also school, financial, and disability systems.

Screen Shot 2019-12-15 at 10_edited.jpg

Multinational CASiRe - Will Emerging Tools Harmonize Treatment for Sickle Cell Disease Patients?

Noted pediatric hematologist, Dr. Raffaella Colombatti provides perspective on her multinational CASiRe study (Consortium for the Advancement of Sickle Cell Research) of sickle cell disease in Europe. Dr. Colombatti speaks to the need for ethnic, cultural and geographical backgrounds to be considered when administering care to SCD populations.

Screen Shot 2019-12-15 at 10_edited.jpg

Worldwide SWAY Survey: Sickle Cell Disease Deeply Impacting Patient Lives

Dr. Ify Osunkwo, Director of the Sickle Cell Disease Enterprise at Levine Cancer Institute, shares insights on an international study spanning from the United States to the Middle East. Over 2100 patients from 16 countries were surveyed, producing some insightful data. Watch Dr. Osunkwo, leader of this study speak to how this new data might help ease the daily physical and emotional struggles SCD patients face.

Thank you for visiting our Sickle Cell Focus Area.


We are working hard to bring you meaningful educational content. Please check back or be sure to sign up for our newsletter for more information.